Literature DB >> 34173695

European guideline and expert statements on the management of narcolepsy in adults and children.

Claudio L A Bassetti1, Ulf Kallweit2, Luca Vignatelli3, Giuseppe Plazzi3,4, Michel Lecendreux5,6, Elisa Baldin3, Leja Dolenc-Groselj7,8, Poul Jennum9, Ramin Khatami1,10, Mauro Manconi1,11, Geert Mayer12,13, Markku Partinen14, Thomas Pollmächer15, Paul Reading16, Joan Santamaria17, Karel Sonka18, Yves Dauvilliers19, Gert J Lammers20,21.   

Abstract

BACKGROUND AND AIM: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children.
METHODS: The European Academy of Neurology (EAN), European Sleep Research Society (ESRS) and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach.
RESULTS: A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong), methylphenidate, amphetamine derivates (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) excessive daytime sleepiness in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivates (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions.
CONCLUSION: The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Entities:  

Keywords:  European; cataplexy; guideline; management; narcolepsy

Year:  2021        PMID: 34173695     DOI: 10.1111/ene.14888

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  10 in total

1.  Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review.

Authors:  Ramona Cordani; Marco Veneruso; Flavia Napoli; Natascia Di Iorgi; Claudia Milanaccio; Alessandro Consales; Nicola Disma; Elisa De Grandis; Mohamad Maghnie; Lino Nobili
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

2.  Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

Authors:  Young-A Heo
Journal:  CNS Drugs       Date:  2022-03-31       Impact factor: 6.497

3.  Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis.

Authors:  Zhongxing Zhang; Yves Dauvilliers; Giuseppe Plazzi; Geert Mayer; Gert Jan Lammers; Joan Santamaria; Markku Partinen; Sebastiaan Overeem; Rafael Del Rio Villegas; Karel Sonka; Rosa Peraita-Adrados; Raphaël Heinzer; Aleksandra Wierzbicka; Birgit Högl; Mauro Manconi; Eva Feketeova; Antonio Martins da Silva; Jitka Bušková; Claudio L A Bassetti; Lucie Barateau; Fabio Pizza; Elena Antelmi; Jari K Gool; Rolf Fronczek; Carles Gaig; Ramin Khatami
Journal:  Nat Sci Sleep       Date:  2022-05-31

4.  Characterization of rapid weight gain phenotype in children with narcolepsy.

Authors:  Min Zhang; Marine Thieux; Clara Odilia Inocente; Noemie Vieux; Laura Arvis; Carine Villanueva; Jian-Sheng Lin; Sabine Plancoulaine; Aurore Guyon; Patricia Franco
Journal:  CNS Neurosci Ther       Date:  2022-02-25       Impact factor: 7.035

Review 5.  Pediatric Narcolepsy-A Practical Review.

Authors:  I-Hang Chung; Wei-Chih Chin; Yu-Shu Huang; Chih-Huan Wang
Journal:  Children (Basel)       Date:  2022-06-29

6.  Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort.

Authors:  Carlotta Mutti; Valerio Brunetti; Michela Figorilli; Claudio Liguori; Fabio Pizza; Paola Proserpio; Tommaso Sacco; Giuseppe Pedrazzi; Isabelle Lecomte; Nora Blanchard; Elio Clemente Agostoni; Enrica Bonanni; Diego Centonze; Alessandro Cicolin; Giacomo Della Marca; Luigi Ferini-Strambi; Raffaele Ferri; Gian Luigi Gigli; Francesca Izzi; Rocco Liguori; Raffaele Lodi; Lino Nobili; Liborio Parrino; Fabio Placidi; Monica Puligheddu; Andrea Romigi; Maria Antonietta Savarese; Michele Terzaghi; Giuseppe Plazzi
Journal:  Neurol Sci       Date:  2022-06-25       Impact factor: 3.830

7.  What Works for One May Not Work for Another: A New Warning for Modafinil.

Authors:  Harim Kim; Girma M Ayele; Rediet T Atalay; Siham Hussien; Bereket Tewoldemedhin; Miriam B Michael; Steven M Scharf
Journal:  Cureus       Date:  2022-07-26

8.  Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.

Authors:  Rebecca Evans; Haruhide Kimura; Robert Alexander; Ceri H Davies; Hélène Faessel; Deborah S Hartman; Takashi Ishikawa; Emiliangelo Ratti; Kohei Shimizu; Motohisa Suzuki; Shinichiro Tanaka; Hiroshi Yukitake; Yves Dauvilliers; Emmanuel Mignot
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

Review 9.  Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation.

Authors:  Daniela Latorre; Federica Sallusto; Claudio L A Bassetti; Ulf Kallweit
Journal:  Semin Immunopathol       Date:  2022-04-21       Impact factor: 11.759

Review 10.  Impact of L-carnitine in narcolepsy treatment: a systematic review on the effectiveness and safety.

Authors:  Cristina Salles; Maria Clara Freitas; Miguel Meira E Cruz
Journal:  Sleep Sci       Date:  2022 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.